Cargando…

Impact of an Altered Wnt1/β-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma

In renal cell carcinoma (RCC), single members of the Wnt/β-catenin signaling cascade were recently identified to contribute to cancer progression. However, the role of Wnt1, one of the key ligands in β-catenin regulation, is currently unknown in RCC. Therefore, alterations of the Wnt1/β-catenin axis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kruck, Stephan, Eyrich, Christian, Scharpf, Marcus, Sievert, Karl-Dietrich, Fend, Falco, Stenzl, Arnulf, Bedke, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709711/ https://www.ncbi.nlm.nih.gov/pubmed/23708097 http://dx.doi.org/10.3390/ijms140610944

Ejemplares similares

A Rare Case of Synchronous Renal Cell Carcinoma of the Bladder Presenting With Gross Hematuria
por: Kruck, Stephan, et al.
Publicado: (2013)

MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma
por: Fisel, Pascale, et al.
Publicado: (2015)

Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma
por: Büttner, Florian, et al.
Publicado: (2018)

Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2015)

Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy
por: Thaiss, Wolfgang M., et al.
Publicado: (2022)

The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma
por: Stühler, Viktoria, et al.
Publicado: (2021)

Is a single portal venous phase in contrast-enhanced CT sufficient to detect metastases or recurrence in clear cell renal cell carcinoma? – a single-center retrospective study
por: Hagen, Florian, et al.
Publicado: (2022)

Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases
por: Maas, Moritz, et al.
Publicado: (2023)

Nicotinamide‐N‐methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma
por: Reustle, Anna, et al.
Publicado: (2022)

Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes
por: Winter, Stefan, et al.
Publicado: (2016)

Versatility and clinical effectiveness of a synthetic sealing hemostatic patch as alternative to parenchyma suturing in laparoscopic partial nephrectomy
por: Erne, Eva, et al.
Publicado: (2021)

Circulating and Disseminated Tumor Cells in the Management of Advanced Prostate Cancer
por: Kruck, Stephan, et al.
Publicado: (2012)

Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma
por: Sauter-Meyerhoff, Carolin, et al.
Publicado: (2021)

Economic aspects of bladder cancer: what are the benefits and costs?
por: Sievert, K. D., et al.
Publicado: (2009)

Real world data on IO-based therapy for metastatic renal cell carcinoma
por: Stühler, Viktoria, et al.
Publicado: (2022)

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab
por: Stühler, Viktoria, et al.
Publicado: (2022)

Circulating tumor cells and their role in prostate cancer
por: Maas, Moritz, et al.
Publicado: (2019)

Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?
por: Maas, Moritz, et al.
Publicado: (2021)

T2 mapping for the characterization of prostate lesions
por: Hepp, Tobias, et al.
Publicado: (2022)

Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC
por: Ribback, Silvia, et al.
Publicado: (2021)

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2018)

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy
por: Bedke, Jens, et al.
Publicado: (2013)

Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies
por: Stühler, Viktoria, et al.
Publicado: (2022)

MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients
por: Lukamowicz-Rajska, Magdalena, et al.
Publicado: (2016)

A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
por: Büttner, Florian A., et al.
Publicado: (2022)

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
por: Hegemann, Miriam, et al.
Publicado: (2019)

A Peritoneal Purse-String Suture Prevents Symptomatic Lymphoceles in Retzius-Sparing Robot-Assisted Radical Prostatectomy
por: Harland, Niklas, et al.
Publicado: (2023)

Signal processing in urodynamics: towards high definition urethral pressure profilometry
por: Klünder, Mario, et al.
Publicado: (2016)

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
por: Reustle, Anna, et al.
Publicado: (2020)

CENPA promotes clear cell renal cell carcinoma progression and metastasis via Wnt/β-catenin signaling pathway
por: Wang, Qi, et al.
Publicado: (2021)

p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics
por: Diesing, Karoline, et al.
Publicado: (2021)

Surgical approach in patients with T4 bladder cancer as primary treatment: Disaster or option with improved quality of life
por: Nagele, Udo, et al.
Publicado: (2008)

ARL4C Regulates the Progression of Clear Cell Renal Cell Carcinoma by Affecting the Wnt/β-Catenin Signaling Pathway
por: Zhang, Peizhi, et al.
Publicado: (2022)

Tumor-associated macrophages in clear cell renal cell carcinoma express both gastrin-releasing peptide and its receptor: a possible modulatory role of immune effectors cells
por: Bedke, Jens, et al.
Publicado: (2009)

CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?
por: Geng, Ruizhi, et al.
Publicado: (2022)

Hypertonicity-Affected Genes Are Differentially Expressed in Clear Cell Renal Cell Carcinoma and Correlate with Cancer-Specific Survival
por: Kandabarau, Siarhei, et al.
Publicado: (2019)

On the probability of lymph node negativity in pN0-staged prostate cancer—a theoretically derived rule of thumb for adjuvant needs
por: Paulsen, Frank, et al.
Publicado: (2021)

TLN2 functions as a tumor suppressor in clear cell renal cell carcinoma via inactivation of the Wnt/β-catenin signaling pathway
por: Cai, Jingshuang, et al.
Publicado: (2022)

NEK2 Serves as a Novel Biomarker and Enhances the Tumorigenicity of Clear-CellRenal-Cell Carcinoma by Activating WNT/β-Catenin Pathway
por: Zhou, Jiancheng, et al.
Publicado: (2022)

RUNX2 interacts with SCD1 and activates Wnt/β‐catenin signaling pathway to promote the progression of clear cell renal cell carcinoma
por: Song, Xiandong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d6fnqgc9m7hrinbljokljhif23